- Medical cannabis, encompassing pharmaceutical-grade cannabis products used to treat a variety of conditions such as chronic pain, epilepsy, multiple sclerosis, and cancer-related symptoms, is witnessing growing acceptance across Europe due to evolving regulatory frameworks and increasing clinical validation of its therapeutic benefits
- The demand for medical cannabis in Europe is primarily driven by rising prevalence of chronic illnesses, growing geriatric populations, supportive government policies, and increasing research investments in cannabinoid-based therapies
- Germany dominated the Europe medical cannabis market with the largest revenue share of 27.9% in 2024, supported by a well-established reimbursement framework, widespread physician adoption, and strong patient demand. The country’s leadership in regulatory development and its active import and domestic production ecosystem continue to drive market growth
- Italy is expected to be the fastest-growing country in the Europe medical cannabis market during the forecast period with a CAGR of 9.7% in 2024, driven by domestic production through military facilities, increasing imports, and consistent demand for chronic pain and palliative care treatments
- The natural segment dominated the Europe medical cannabis market with a market share of 69.3% in 2024, attributed to the rising demand for organic and plant-derived therapeutics. Its widespread use is supported by increasing patient preference for naturally sourced treatments and favorable regulatory stances across key European countries such as Germany, Italy, and the Netherlands
